ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2019; 10(27):6858-6864. doi:10.7150/jca.31182 This issue Cite
Research Paper
Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer
1. VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China
2. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China
3. Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, R.P. China
4. Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, R.P. China
5. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China
6. Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China
*Contributed equally to this paper
Citation:
Huang Y, Li W, Quan Q, Zhang B, Yang Q. Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer. J Cancer 2019; 10(27):6858-6864. doi:10.7150/jca.31182. https://www.jcancer.org/v10p6858.htm
Other stylesAbstract
Background: Inflammation might play an important role in promoting cancer growth partly by affecting tumor angiogenesis. We explored the role of Glasgow prognostic score (GPS) in metastatic colorectal cancer patients receiving first-linebevacizumab.
Methods: All consecutive metastatic colorectal cancer patients treated with first-line chemotherapy plus or not plus bevacizumab were eligible. Pre-treatment GPS were collected for all cases.
Results: In the chemotherapy group for patients with GPS of 0, 1 and 2, median progression-free survival (PFS) was 8.67, 8.10, and 8.27months, respectively (P = 0.17). Median overall survival (OS) was 24.87, 23.30, and 17.93months, respectively (P = 0.04). In the bevacizumab group, median PFS was 11.83, 8.10, and 6.87 months, respectively (P = 0.01), and median OS was 30.80, 19.47, and 18.67 months, respectively (P = 0.03).In whole group patients with a GPS of 0, both PFS and OS were in favor of patients treated with bevacizumab plus chemotherapy compared with who treated with chemotherapy alone (PFS 11.83 vs. 8.67 months, p=0.03; OS 30.80 vs. 24.87 months, p=0.04).
Conclusion: GPS of 0 was correlated with good prognosis. Bevacizumab added a survival advantage only in metastatic colorectal cancer patients with a GPS of 0.
Keywords: Glasgow prognostic score, bevacizumab, first-line therapy, metastatic colorectal cancer
Citation styles
APA
Huang, Y., Li, W., Quan, Q., Zhang, B., Yang, Q. (2019). Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer. Journal of Cancer, 10(27), 6858-6864. https://doi.org/10.7150/jca.31182.
ACS
Huang, Y.; Li, W.; Quan, Q.; Zhang, B.; Yang, Q. Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer. J. Cancer 2019, 10 (27), 6858-6864. DOI: 10.7150/jca.31182.
NLM
Huang Y, Li W, Quan Q, Zhang B, Yang Q. Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer. J Cancer 2019; 10(27):6858-6864. doi:10.7150/jca.31182. https://www.jcancer.org/v10p6858.htm
CSE
Huang Y, Li W, Quan Q, Zhang B, Yang Q. 2019. Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer. J Cancer. 10(27):6858-6864.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.